Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

M. P. De Vetten, J. H. Jansen, B. A. Van Der Reijden, M. S. Berger, J. M.J.M. Zijlmans, B. Löwenberg

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-1og tumour mass reduction in bone marrow.

Original languageEnglish (US)
Pages (from-to)277-279
Number of pages3
JournalBritish Journal of Haematology
Volume111
Issue number1
DOIs
StatePublished - 2000

Keywords

  • Acute myeloid leukaemia
  • Gemtuzumab ozogamicin (CMA-676)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)'. Together they form a unique fingerprint.

Cite this